---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-073016"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2023-12-26T23:59:59+00:00"
generated_at: "2026-06-07T07:27:00.444333+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology amends loan agreement; extends draw period to June 30, 2024 and adds ASPEN-06 milestone

## Summary
- Term A Loan draw period extended from Dec 31, 2023 to June 30, 2024.
- Future Term A funding requires Phase 2 of ASPEN-06 in gastric cancer to be ongoing or have positive data.
- Contingency fee of $600,000 payable to lenders if prepaid outside refinancing with Oxford and SVB.
- Remaining undrawn Term A commitment reallocated to Term B and C after June 30, 2024.

## SEC filing metadata
- accession: 0000950170-23-073016
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2023-12-26T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000095017023073016/0000950170-23-073016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000095017023073016/alxo-20231222.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-073016
- JSON: https://secwatch.observer/filing/0000950170-23-073016.json
- Plain text: https://secwatch.observer/filing/0000950170-23-073016.txt

## Key facts
- Debt Financings
  ALX ONCOLOGY HOLDINGS INC incurred term loan.
  - Instrument: term loan
  - Event: incurrence
  source text: The Third Amendment amends the Loan Agreement to, among other things, (i) extend the draw period for the Term A Loans from December 31, 2023 to June 30, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810182/000095017023073016/0000950170-23-073016-index.htm
- Material Agreements
  ALX ONCOLOGY HOLDINGS INC amended Third Amendment to Loan and Security Agreement with Oxford Finance LLC (effective 2023-12-22).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: Oxford Finance LLC
  - Effective: 2023-12-22
  source text: On December 22, 2023, ALX Oncology Holdings Inc. (the “Company”) and its indirectly wholly-owned subsidiary, ALX Oncology Inc. (“Borrower”) entered into the Third Amendment to Loan and Security Agreement (the “Third Amendment”) by and among the Company as a guarantor, the Borrower, Oxford Finance LLC ("Oxford"), as collateral agent (“Agent”), and the lenders party thereto.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810182/000095017023073016/0000950170-23-073016-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.